We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current PBE market cap is 271.57M. The company's latest EPS is USD -1.4993 and P/E is -44.83.
| Quarter End | |||||
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | |||||
| Operating Income | |||||
| Net Income |
| Year End April 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 1.32M | 719k | 1.17M | 1.18M | 1.04M |
| Operating Income | 0 | 0 | 0 | 0 | 0 |
| Net Income | 2.18M | 86.4M | -74.81M | 23.92M | -6.06M |
| Quarter End | |||||
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | |||||
| Total Liabilities | |||||
| Total Equity |
| Year End April 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 227.25M | 330.82M | 262.34M | 289.09M | 293.37M |
| Total Liabilities | 6.64M | 42.98M | 54.15M | 37.43M | 47.56M |
| Total Equity | 220.61M | 287.83M | 208.19M | 251.66M | 245.81M |
| Market Cap | 271.57M |
| Price to Earnings Ratio | -44.83 |
| Price to Sales Ratio | 262.17 |
| Price to Cash Ratio | 44.81k |
| Price to Book Ratio | 1.1 |
| Dividend Yield | - |
| Shares Outstanding | 4.04M |
| Average Volume (1 week) | 6.31k |
| Average Volume (1 Month) | 5.41k |
| 52 Week Change | 2.28% |
| 52 Week High | 72.8399 |
| 52 Week Low | 59.3199 |
| Spread (Intraday) | 2.67 (3.9%) |
| Company Name | Invesco Biotechnology and Genome ETF |
| Address |
155 federal st boston, massachusetts 02110 |
| Website | https://www.invesco.com |
| Industry | mgmt invt offices, open-end (6722) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
